Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Citigroup Ups Pain Therapeutics to Hold


Citigroup upgraded Pain Therapeutics (PTIE) to hold from sell, after news that the drug maker's painkiller Oxytrex failed to in a trial.

While citing these "clouded results," analyst Andrew Swanson says that management has affirmed its plan to continue developing the drug, with a new trial expected to begin in 2006. He says he's always assumed a third trial would be required for approval of the drug; as such, he keeps his forecasts on the company's earnings, which assume a second quarter 2008 launch for Oxytrex.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus